Brain Tumor Pathology

Papers
(The median citation count of Brain Tumor Pathology is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Clinical, histopathological and molecular risk factors for recurrence of pilocytic astrocytomas: brainstem/spinal location, nestin expression and gain of 7q and 19 are associated with early tumor recu44
Preface for Brain Tumor Pathology vol.41 issue 221
IDH wild-type lower-grade gliomas with glioblastoma molecular features: a systematic review and meta-analysis18
Correlation of MTAP immunohistochemical deficiency with CDKN2A homozygous deletion and clinicopathological features in pleomorphic xanthoastrocytoma14
Droplet digital PCR assay for detecting TERT promoter mutations in patients with glioma14
The oligodendroglial histological features are not independently predictive of patient prognosis in lower-grade gliomas13
Double-hit primary central nervous system lymphoma with histogenetically proven bone marrow infiltration: a case report and a review of the literature13
Central nervous system ALK-negative anaplastic large cell lymphoma with IRF4/DUSP22 rearrangement13
Beyond the WHO 2021 classification of the tumors of the central nervous system: transitioning from the 5th edition to the next12
Primary central nervous system lymphoma: clinicopathological and genomic insights for therapeutic development11
Histopathological predictors of progression-free survival in atypical meningioma: a single-center retrospective cohort and meta-analysis11
FISH analysis reveals CDKN2A and IFNA14 co-deletion is heterogeneous and is a prominent feature of glioblastoma11
A clinicopathological analysis of supratentorial ependymoma, ZFTA fusion-positive: utility of immunohistochemical detection of CDKN2A alterations and characteristics of the immune microenvironment11
Correction: Beyond the WHO 2021 classification of the tumors of the central nervous system: transitioning from the 5th edition to the next10
Lynch syndrome-associated chordoma with high tumor mutational burden and significant response to immune checkpoint inhibitors10
Predicting BRAF V600E mutation in glioblastoma: utility of radiographic features10
Anti-angiogenic and macrophage-based therapeutic strategies for glioma immunotherapy10
Comparative analyses of immune cells and alpha-smooth muscle actin-positive cells under the immunological microenvironment between with and without dense fibrosis in primary central nervous system lym8
Pediatric diffuse glioma with EP300::BCOR fusion manifesting as low-grade epilepsy-associated neuroepithelial tumor: a case presentation8
Tectal glioma: clinical, radiological, and pathological features, and the importance of molecular analysis7
Three-dimensional visualization of human brain tumors using the CUBIC technique7
The 2021 WHO classification of tumors, 5th edition, central nervous system tumors: the 10 basic principles7
Preface for Brain Tumor Pathology vol. 39 issue 27
Revisiting vimentin: a negative surrogate marker of molecularly defined oligodendroglioma in adult type diffuse glioma7
Spontaneous malignant transformation of trigeminal schwannoma: consideration of responsible gene alterations for tumorigenesis—a case report6
Revisiting the definition of glioma recurrence based on a phylogenetic investigation of primary and re-emerging tumor samples: a case report6
Easy-to-use machine learning system for the prediction of IDH mutation and 1p/19q codeletion using MRI images of adult-type diffuse gliomas6
Timing of H3K27me3 loss in secondary anaplastic meningiomas6
Clinical and radiological findings of glioblastomas harboring a BRAF V600E mutation5
Astroblastoma with MN1::BEND2 in an elderly patient: A case report and review of the literature5
Integrated analysis of multiple methods reveals characteristics of the immune microenvironment in medulloblastoma5
Spinal cord astroblastoma with EWSR1-BEND2 fusion classified as HGNET-MN1 by methylation classification: a case report5
Utility of genome-wide DNA methylation profiling for pediatric-type diffuse gliomas5
Status of alternative angiogenic pathways in glioblastoma resected under and after bevacizumab treatment5
Association between IDH mutational status and tumor-associated epilepsy or venous thromboembolism in patients with grade II and III astrocytoma5
Clinical and radiological features of intracranial ancient schwannomas: a single-institution, retrospective analysis5
Progression of long-term “untreated” oligodendroglioma cases: possible contribution of genomic instability4
Rise of oligodendroglioma hypermutator phenotype from a subclone harboring TP53 mutation after TMZ treatment4
An extracranial CNS presentation of the emerging “intracranial” mesenchymal tumor, FET: CREB-fusion positive4
Emerging glioneuronal and neuronal tumors: case-based review4
A primary DICER1-sarcoma with KRAS and TP53 mutations in a child with suspected ECCL4
Preface4
Aggressive nonfunctioning pituitary neuroendocrine tumors4
Clinicopathological risk factors for a poor prognosis of primary central nervous system lymphoma in elderly patients in the Tohoku and Niigata area: a multicenter, retrospective, cohort study of the T4
Impact of tumor markers on diagnosis, treatment and prognosis in CNS germ cell tumors: correlations with clinical practice and histopathology4
Liquid biomarkers in glioma3
Visualizing the endothelial glycocalyx in human glioma vasculature3
Touch imprint cytology is useful for the intraoperative pathological diagnosis of PitNETs’ surgical margins3
Recent advances in liquid biopsy of central nervous system lymphomas: case presentations and review of the literature3
PBRM1 and BAP1: novel genetic mutations in malignant transformation of craniopharyngioma—a case report3
MAPK pathway alterations in polymorphous low-grade neuroepithelial tumor of the young: diagnostic considerations3
Correction to: Epithelioid inflammatory myofibroblastic sarcoma with VCL–ALK fusion of central nervous system: case report and brief review of the literature3
Combination of p38 MAPK inhibitor with PD-L1 antibody effectively prolongs survivals of temozolomide-resistant glioma-bearing mice via reduction of infiltrating glioma-associated macrophages and PD-L13
0.1064760684967